HC Deb 11 March 1993 vol 220 c707W
Mr. Blunkett

To ask the Secretary of State for Health what information has been received, and what guidance has been issued, by her Department regarding the side-effects of the drug, Drinamyl.

Dr. Mawhinney

Drinamyl is the proprietary name for a product containing dexamphetamine and amylobarbitone. This was indicated for mild temporary emotional disturbances but was withdrawn from the market in 1978. The Committee on Safety of Medicines received nine reports of suspected adverse reactions to Drinamyl. A report of a suspected adverse reaction does not necessarily mean that the reaction was caused by the drug. The most important side effects of Drinamyl are dependence and psychosis, and the abuse potential of this type of drug is well recognised. The Department has not issued any specific guidance about the side-effects of Drinamyl.